SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla recalls 7,228 bottles of Solifenacin Succinate tablets

26 Jul 2021 Evaluate

Cipla is recalling 7,228 bottles of Solifenacin Succinate tablets, a medicine used to treat overactive bladder, in the US market due to manufacturing issues. The company is recalling 10 mg, 30-count bottles in the US. The company has initiated the recall on June 10 this year and the USFDA has classified it as a Class II recall.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.

Cipla Share Price

1229.30 -3.60 (-0.29%)
22-Apr-2026 11:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1658.60
Dr. Reddys Lab 1219.95
Cipla 1229.30
Zydus Lifesciences 930.70
Lupin 2309.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×